<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of polycystic ovary syndrome in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of polycystic ovary syndrome in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of polycystic ovary syndrome in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Ehrmann, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William F Crowley, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 10, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The polycystic ovary syndrome (PCOS) is an important cause of androgen excess, menstrual irregularity, and cardiometabolic dysfunction in women. When fully expressed, the manifestations include irregular menstrual cycles, hirsutism, obesity, insulin resistance, and anovulatory infertility.
        </p>
        <p>
         The treatment of PCOS will be reviewed here. The epidemiology and pathogenesis, diagnostic criteria, and clinical manifestations of PCOS are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW OF APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS have multiple abnormalities that require attention, including oligomenorrhea, hyperandrogenism, anovulatory infertility, and metabolic risk factors such as obesity, insulin resistance, dyslipidemia, and impaired glucose tolerance. Weight loss, which can restore ovulatory cycles and improve metabolic risk, is the first-line intervention for most women. Our overall approach is similar to that described by the Endocrine Society Clinical Guidelines [
         <a href="#rid1">
          1
         </a>
         ] and the international guidelines for the assessment and management of PCOS [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H794280451">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall goals of therapy of women with PCOS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amelioration of hyperandrogenic features (hirsutism, acne, scalp hair loss)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of underlying metabolic abnormalities and reduction of risk factors for type 2 diabetes and cardiovascular disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of endometrial hyperplasia and carcinoma, which may occur as a result of chronic anovulation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraception for those not pursuing pregnancy, as women with oligomenorrhea ovulate intermittently and unwanted pregnancy may occur
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ovulation induction for those pursuing pregnancy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H76807877">
         <span class="h2">
          Lifestyle changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest diet and exercise for weight reduction as the first step for overweight and obese women with PCOS. Available evidence suggests that lifestyle interventions (diet, exercise, and behavioral interventions) are more effective than minimal treatment for weight loss and for improving insulin resistance and hyperandrogenism [
         <a href="#rid3">
          3
         </a>
         ]. In addition, there appear to be reproductive benefits as well. (See
         <a class="local">
          'Weight reduction'
         </a>
         below and
         <a class="local">
          'Weight loss'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H794280459">
         <span class="h2">
          Oral contraceptives and risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combined estrogen-progestin oral contraceptives (COCs) are the mainstay of pharmacologic therapy for women with PCOS for managing hyperandrogenism and menstrual dysfunction and for providing contraception. COCs are associated with an increased risk of venous thromboembolism (VTE) in all users but particularly in obese women. There have been concerns that the presence of PCOS per se may represent an additional independent risk factor for VTE, but available data do not support this concept. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
         Our approach to the use of COCs in women with PCOS is the same as in women without PCOS. Risk factors for VTE including obesity, patient age, and family history of VTE should be assessed. We currently suggest using caution if COCs are prescribed to obese women (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ) over age 40 years because these women are at particularly high risk for VTE. Other relative and absolute contraindications to COC use are outlined in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=7421" target="_blank">
          Centers for Disease Control and Prevention (CDC) United States Medical Eligibility Criteria for Contraceptive Use
         </a>
         . Alternatives to COCs include cyclic progestin therapy, continuous progestin therapy (progestin-only pills [the "mini-pill"]), or a progestin-releasing intrauterine device (IUD). Cyclic progestin therapy can induce regular withdrawal uterine bleeding and reduce the risk of endometrial hyperplasia. Both continuous progestin therapy (eg, a progestin-only pill such as
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         0.35 mg/day) and the progestin-releasing IUD provide contraception and reduce the risk of endometrial hyperplasia. (See
         <a class="local">
          'Endometrial protection'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056430032">
         <span class="h2">
          Patient satisfaction with care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS commonly report long delays in diagnosis and dissatisfaction with their care. In a cross-sectional study of 134 women with PCOS and 198 controls without PCOS who completed an online evaluation of their health care providers, those with PCOS had less trust in their primary care providers, perceived them as less qualified to treat PCOS-related health concerns, and argued with them more often [
         <a href="#rid4">
          4
         </a>
         ]. These observations highlight opportunities for improving care for women with PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Delays in diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H771175086">
         <span class="h1">
          WOMEN NOT PURSUING PREGNANCY
         </span>
        </p>
        <p class="headingAnchor" id="H771175465">
         <span class="h2">
          Menstrual dysfunction
         </span>
        </p>
        <p class="headingAnchor" id="H771175559">
         <span class="h3">
          Endometrial protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The chronic anovulation seen in PCOS is associated with an increased risk of endometrial hyperplasia and possibly endometrial cancer. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Endometrial cancer risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">
          "Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Chronic anovulation'
         </a>
         .)
        </p>
        <p>
         We suggest combined estrogen-progestin oral contraceptives (COCs) as first-line therapy for menstrual dysfunction and endometrial protection [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         COCs provide a number of benefits in women with PCOS, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daily exposure to progestin, which antagonizes the endometrial proliferative effect of estrogen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraception in those not pursuing pregnancy, as women with oligomenorrhea ovulate intermittently and unwanted pregnancy may occur
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous benefits for hyperandrogenic manifestations (see
         <a class="local">
          'Androgen excess'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         COCs affect insulin sensitivity, carbohydrate metabolism, and lipid metabolism; the effects depend upon the estrogen dose and androgenicity of the progestin. However, there is no evidence that women with PCOS are at greater risk for either metabolic adverse effects or cardiovascular complications of COCs. (See
         <a class="local">
          'Metabolic effects of COCs in PCOS'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
         Absence of pregnancy should be documented before COCs are begun.
        </p>
        <p>
         An approach to starting COCs in women with PCOS is described below (see
         <a class="local">
          'Choice of oral contraceptive'
         </a>
         below). Risks and side effects of COCs (including unscheduled bleeding) are similar to those for women without PCOS. Unscheduled bleeding and an overview of estrogen-progestin COCs are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         .)
        </p>
        <p>
         For women with PCOS who choose not to or cannot take COCs, alternative treatments for endometrial protection are intermittent or continuous progestin therapy, or a progestin-releasing intrauterine device (IUD) [
         <a href="#rid5">
          5
         </a>
         ]. In this setting, we recommend
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (5 to 10 mg) for 10 to 14 days every one to two months. An alternative, but one that has been less well studied, is natural micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         200 mg (given for the same duration every one to two months). Patients should be made aware that progestin therapy alone will not reduce the symptoms of acne or hirsutism, nor will it provide contraception. However, continuous progestin therapy with
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         0.35 mg daily provides both contraception and endometrial protection. This is a progestin-only contraceptive that is also referred to as the "mini-pill." An alternative progestin option that provides both endometrial protection and contraception are the levonorgestrel-releasing IUDs. (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection", section on 'Endometrial protection'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is a potential alternative to restore menstrual cyclicity as it restores ovulatory menses in approximately 30 to 50 percent of women with PCOS [
         <a href="#rid6">
          6,7
         </a>
         ]. Its ability to provide endometrial protection is less well established, and we therefore consider it to be second-line therapy [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome"
         </a>
         .)
        </p>
        <p>
         When
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         is used, we suggest monitoring to confirm that ovulatory cycles have been established. This can be done with luteal phase serum
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         measurements or transvaginal ultrasound. (See
         <a class="medical medical_review" href="/z/d/html/7437.html" rel="external">
          "Evaluation of the menstrual cycle and timing of ovulation", section on 'Assessment of ovulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'Oligomenorrhea'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Androgen excess
         </span>
        </p>
        <p class="headingAnchor" id="H10997524">
         <span class="h3">
          Hirsutism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of hirsutism is consistent with the 2018 Endocrine Society Clinical Practice Guidelines on Hirsutism, which suggest a COC as first-line pharmacologic therapy for most women [
         <a href="#rid10">
          10
         </a>
         ]. In addition, both the Endocrine Society Clinical Practice Guidelines on the Diagnosis and Treatment of Polycystic Ovary Syndrome and international guidelines for the assessment and management of PCOS [
         <a href="#rid2">
          2
         </a>
         ] suggest COCs as first-line therapy for hirsutism [
         <a href="#rid1">
          1
         </a>
         ]. An antiandrogen is then added after six months if the cosmetic response is suboptimal (see
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         ). COCs and an antiandrogen may sometimes be started simultaneously at the outset, particularly when the cutaneous manifestations are bothersome to the patient. However, we typically postpone starting the antiandrogen until completion of at least one month of COC. A serum or urine pregnancy test should be obtained in women with oligomenorrhea or amenorrhea prior to starting either the COC or
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
         For women with hirsutism and contraindications to COCs, we sometimes use
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         alone, but an alternative form of contraception is essential because, if pregnancy occurs, an antiandrogen such as spironolactone could prevent development of normal external genitalia in a male fetus. Spironolactone alone does not regularize menstrual cycles, and in fact, it is sometimes associated with menstrual irregularities.
        </p>
        <p class="headingAnchor" id="H2412576634">
         <span class="h3">
          Choice of oral contraceptive
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically start with a COC containing 20 mcg of ethinyl estradiol combined with a progestin such as
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         or norethindrone acetate, progestins that have lower androgenicity, but similar VTE risk compared with levonorgestrel-containing COCs  (
         <a class="graphic graphic_table graphicRef78782" href="/z/d/graphic/78782.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
         Progestins with lower androgenicity include desogestrel,
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         , and
         <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">
          drospirenone
         </a>
         , but all have been associated with a possible higher risk of venous thromboembolism (VTE). Norgestimate is a progestin with low androgenicity and similar VTE risk to
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         and
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         . However, there are currently no COCs containing 20 mcg of ethinyl estradiol with norgestimate.
        </p>
        <p>
         Higher doses of ethinyl estradiol (30 to 35 mcg) are needed in some women for optimal suppression of ovarian androgens and management of hyperandrogenic features. Although transdermal or vaginal ring preparations are potential options, they have not been well studied for the management of hirsutism. The risk of VTE with the transdermal and vaginal ring preparations appear to be similar to COCs containing
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings", section on 'Cardiovascular and thromboembolic events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Risk of venous thrombotic events'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H76807921">
         <span class="h3">
          Antiandrogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         After six months, if the patient is not satisfied with the clinical response to COC monotherapy (for hyperandrogenic symptoms), we typically add
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         50 to 100 mg twice daily. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
         Other available antiandrogens include
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         , which inhibits 5-alpha-reductase type 2, the enzyme that converts testosterone to dihydrotestosterone (DHT), and
         <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">
          dutasteride
         </a>
         , an inhibitor of both 5-alpha-reductase types 1 and 2. No clinical trial data are available for dutasteride use in hirsute women. These drugs should never be used in women who are not using reliable contraception, as there is a substantial risk of preventing the development of normal male external genitalia during early pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          Cyproterone acetate
         </a>
         is an antiandrogen that is available in most countries, but not the United States.
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         is also effective, but we recommend not using it because of its potential hepatotoxicity. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Antiandrogens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2412576757">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gonadotropin-releasing hormone (GnRH) agonists are also sometimes used to suppress ovarian androgen production; "add-back" estrogen-progestin therapy is necessary to avoid bone loss and estrogen deficiency symptoms. Although this approach is effective, it is limited by its complexity and cost. (See
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Treatments not routinely recommended'
         </a>
         .)
        </p>
        <p>
         Although some clinicians use
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         to treat hirsutism, the Endocrine Society Clinical Practice Guidelines suggest against its routine use as it is associated with minimal or no benefit and is less effective than treatment with COCs and/or antiandrogens [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'Hirsutism'
         </a>
         .)
        </p>
        <p>
         Hirsutism can also be treated by removal of hair by mechanical means such as shaving, waxing, depilatories, electrolysis, or laser treatment. In addition, eflornithine hydrochloride cream (13.9%) is a topical drug that inhibits hair growth. It is not a depilatory and must be used indefinitely to prevent regrowth. (See
         <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">
          "Removal of unwanted hair"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women", section on 'Role of direct hair removal methods'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10997534">
         <span class="h3">
          Acne and androgenetic alopecia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of acne and scalp hair loss (androgenetic alopecia) in women with PCOS are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">
          "Acne vulgaris: Management of moderate to severe acne in adolescents and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540902862">
         <span class="h2">
          Metabolic abnormalities
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss, which can restore ovulatory cycles and improve metabolic risk, is the first-line intervention for most women. The approach to obesity management is the same as that for patients without PCOS, starting with lifestyle changes (diet and exercise) [
         <a href="#rid11">
          11
         </a>
         ], followed by pharmacotherapy, and, when necessary, bariatric surgery [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Weight reduction'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">
          "Outcomes of bariatric surgery", section on 'Polycystic ovary syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H70413157">
         <span class="h4">
          Weight reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest weight-loss strategies using calorie-restricted diets combined with exercise for women with PCOS and obesity. Although there are no large randomized trials of exercise-specific interventions, a systematic review of exercise therapy in PCOS concluded that there may be modest weight loss and improvements in ovulation and insulin sensitivity [
         <a href="#rid13">
          13
         </a>
         ]
         <em>
          .
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise", section on 'Adding exercise to diet is only minimally beneficial for weight loss'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy"
         </a>
         .)
        </p>
        <p>
         Even modest weight loss (5 to 10 percent reduction in body weight) in women with PCOS may result in restoration of normal ovulatory cycles [
         <a href="#rid14">
          14-16
         </a>
         ] and improved pregnancy rates [
         <a href="#rid17">
          17
         </a>
         ] in short-term studies. However, the response to weight loss is variable; not all individuals have restoration of ovulation or menses despite similar weight reduction [
         <a href="#rid11">
          11,12,18
         </a>
         ]. In addition, there are no randomized trials and no long-term data on reproductive or metabolic outcomes with weight loss.
        </p>
        <p>
         Weight loss results in a decrease in serum androgen concentrations and, in some instances, improvements in hirsutism. However, data demonstrating an improvement in hirsutism are limited [
         <a href="#rid3">
          3,11
         </a>
         ].
        </p>
        <p>
         There is no good evidence that one type of diet is superior to another for women with PCOS. Low-carbohydrate diets have become very popular for women with PCOS, based upon the notion that less carbohydrate leads to less hyperinsulinemia and therefore less insulin resistance. However, a 12-week study of a high protein/low carbohydrate diet (30 percent protein, 40 percent carbohydrate, 30 percent fat) and a low protein/high carbohydrate diet (15 percent protein, 55 percent carbohydrate, 30 percent fat) were equally effective for weight loss, improvements in menstrual cyclicity, insulin resistance, dyslipidemia, and abdominal fat in one study of 28 overweight women with PCOS [
         <a href="#rid19">
          19
         </a>
         ]. It is not known if an extremely low carbohydrate diet would be any more effective for these endpoints. (See
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy", section on 'Low-carbohydrate diets'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H531240920">
         <span class="h5">
          Bariatric surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bariatric surgery is another strategy for weight loss in women with PCOS. In one study of 17 obese women with PCOS with a mean body mass index (BMI) of 50.7 kg/m
         <sup>
          2
         </sup>
         , bariatric surgery was associated with a mean weight loss after 12 months of 41±9 kg, restoration of ovulatory cycles, and improvements in insulin resistance, hyperandrogenemia, and hirsutism scores [
         <a href="#rid12">
          12
         </a>
         ]. A retrospective chart review and meta-analysis of 29 studies reported similar benefits for women with PCOS [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/586.html" rel="external">
          "Bariatric surgery for management of obesity: Indications and preoperative preparation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">
          "Outcomes of bariatric surgery", section on 'Polycystic ovary syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h4">
          Insulin resistance/type 2 diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several drugs, including biguanides (
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         ) and thiazolidinediones (
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          pioglitazone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         ), can reduce insulin levels in women with PCOS. These drugs may also reduce ovarian androgen production (and serum free testosterone concentrations) and restore normal menstrual cyclicity [
         <a href="#rid22">
          22-25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Although there had been widespread enthusiasm and use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         for a number of indications in PCOS, clinical data no longer support this approach. A detailed discussion of metformin use in PCOS is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome"
         </a>
         .)
        </p>
        <p>
         Strategies recommended by the American Diabetes Association (ADA) for prevention of type 2 diabetes are discussed separately. The approach in women with PCOS is the same as for women without PCOS. (See
         <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">
          "Prevention of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Thiazolidinediones have been less well studied than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , but they appear to improve insulin sensitivity and hyperandrogenemia [
         <a href="#rid22">
          22-28
         </a>
         ]. However, because of limited clinical data, potential weight gain, and a possible association with cardiovascular adverse events, we do not recommend the use of thiazolidinediones in women with PCOS who do not have diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Though not specifically approved for PCOS,
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         is approved for individuals with a BMI of 30 kg/m
         <sup>
          2
         </sup>
         or greater. Limited data in women with PCOS suggest that liraglutide results in greater weight loss than placebo [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy", section on 'Liraglutide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h4">
          Metabolic effects of COCs in PCOS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In healthy women, combined estrogen-progestin oral contraceptive (COC) use decreases insulin sensitivity, but in general, this decrease is not clinically significant [
         <a href="#rid31">
          31
         </a>
         ]. It has been assumed that COC use would also worsen insulin sensitivity in women with PCOS, although data are conflicting, with studies showing an improvement [
         <a href="#rid32">
          32
         </a>
         ], worsening [
         <a href="#rid33">
          33
         </a>
         ], or no change [
         <a href="#rid34">
          34
         </a>
         ] in insulin sensitivity. When compared with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , COCs may be less beneficial for insulin sensitivity, but better for androgen suppression and menstrual cycle control [
         <a href="#rid35">
          35
         </a>
         ]. There are also theoretical concerns that women with PCOS may be at particular risk for cardiovascular complications with COCs, given their other underlying cardiovascular risk factors. However, there are no COC risk data specific to women with PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
         The effects of combination COC-metformin therapy are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'Adding metformin to oral contraceptives'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5944834">
         <span class="h3">
          Dyslipidemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment of dyslipidemia in women with PCOS is the same as for other patients with dyslipidemia. Exercise and weight loss are the first-line approach, followed by pharmacotherapy, if needed. (See
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5944842">
         <span class="h4">
          Statins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Statins are effective for dyslipidemia in women with PCOS but do not appear to have other clinically important metabolic or endocrine effects. In a meta-analysis of four trials in 244 women randomly assigned to a statin (
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         ) or placebo for 6 to 12 months, statin therapy decreased serum low-density lipoprotein (LDL) and triglycerides, but had no effect on high-density lipoprotein (HDL), fasting insulin, or C-reactive protein. A small decrease in serum testosterone was observed, but there were no improvements in menstrual cycle regularity, ovulation, acne, hirsutism, or BMI [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H226109">
         <span class="h3">
          Obstructive sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep apnea, a common disorder in women with PCOS, is an important determinant of insulin resistance, glucose intolerance, and type 2 diabetes (see
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         ). In one report of women with PCOS and obstructive sleep apnea, treatment with continuous positive airway pressure (CPAP) improved insulin sensitivity and reduced diastolic blood pressure [
         <a href="#rid37">
          37
         </a>
         ]. Similar benefit was reported in a meta-analysis of eight studies [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16744851">
         <span class="h3">
          Nonalcoholic steatohepatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of nonalcoholic steatohepatitis (NASH) appears to be increased in women with PCOS. Both weight loss and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         use appear to improve metabolic and hepatic function in these women [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Nonalcoholic fatty liver disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H957563">
         <span class="h2">
          Depression/anxiety
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is evidence that women with PCOS have impaired quality of life and higher rates of depression and anxiety when compared with women of similar BMI without PCOS [
         <a href="#rid41">
          41
         </a>
         ]. However, the efficacy and safety of antidepressant therapy has not yet been established in women with PCOS and anxiety or depression [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Psychosocial issues'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Depression and anxiety disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540903132">
         <span class="h1">
          WOMEN PURSUING PREGNANCY
         </span>
        </p>
        <p class="headingAnchor" id="H691428547">
         <span class="h2">
          Weight loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         For anovulatory women with PCOS who are overweight or obese, we suggest weight loss prior to initiating ovulation induction therapy. The approach to obesity management is the same as that for patients without PCOS, starting with lifestyle changes (diet and exercise) [
         <a href="#rid11">
          11
         </a>
         ], followed by pharmacotherapy (if not pursuing pregnancy), and, when necessary, bariatric surgery [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Weight reduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">
          "Outcomes of bariatric surgery", section on 'Polycystic ovary syndrome'
         </a>
         .)
        </p>
        <p>
         Even modest weight loss of 5 to 10 percent has been associated with an improvement in metabolic status [
         <a href="#rid43">
          43
         </a>
         ], a reduction in serum androgen concentrations, and resumption of ovulation in some studies [
         <a href="#rid11">
          11,12,14-19,44,45
         </a>
         ]. Not all women develop ovulatory cycles despite similar degrees of weight loss
         <em>
         </em>
         [
         <a href="#rid11">
          11,12,16,18
         </a>
         ]
         <em>
          .
         </em>
         In addition, data on pregnancy rates and outcomes have been limited [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         However, a post hoc comparison of two multicenter, concurrent trials in overweight/obese women with PCOS and anovulatory infertility reported higher ovulatory and live birth rates with pretreatment lifestyle modification and weight loss when compared with immediate treatment with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate [
         <a href="#rid46">
          46
         </a>
         ]. The two concurrent trials included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Treatment of Hyperandrogenism versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (OWL-PCOS) Women, an open-label study of overweight or obese women with PCOS and anovulatory infertility assigned to 16 weeks of pretreatment with continuous oral contraceptives (COCs; n = 47), lifestyle modification (including caloric restriction, antiobesity medication, behavioral medication, and exercise; n = 48), or the combination of both (COCs and lifestyle; n = 47) followed by up to four cycles of
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate for ovulation induction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial (n = 187), a double-blinded trial of up to five cycles of
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         or
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         . Data was extracted only from patients in the clomiphene treatment group who met the body mass index (BMI) criteria for the OWL-PCOS study. Only the first four clomiphene cycles were analyzed.
        </p>
        <p>
        </p>
        <p>
         In PPCOS II, after four cycles of
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         (with no pretreatment), the cumulative per-cycle ovulatory and live birth rates were 45 and 10.2 percent; (227 of 619 cycles, 19 of 187 patients). In OWL-PCOS, a 16-week pretreatment lifestyle intervention resulted in an approximate 6.5 percent weight loss from baseline and improvements in ovulatory and live birth rates (62 and 25 percent, respectively; 80 of 129 cycles and 12 of 48 patients). Pretreatment with oral contraceptives (alone or combined with lifestyle intervention) did not affect outcomes.
        </p>
        <p>
         Although we encourage weight loss in obese woman with PCOS and anovulatory infertility, our approach is somewhat different in older women (≥37 years) or in those whose testing shows diminished ovarian reserve. In these settings, we typically offer either immediate ovulation induction or a short (three-month) attempt at weight loss followed by ovulation induction. We do not suggest a longer attempt to lose weight.
        </p>
        <p class="headingAnchor" id="H2412577776">
         <span class="h2">
          Ovulation induction medications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For oligo-ovulatory women with PCOS undergoing ovulation induction, we now suggest
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         as first-line therapy over
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate, regardless of the patient's BMI. Before starting letrozole, the clinician
         <strong>
          must
         </strong>
         discuss that this use of the drug is not approved by the US Food and Drug Administration (FDA) for this purpose and that there is an available alternative (clomiphene citrate). (See
         <a class="medical medical_review" href="/z/d/html/7425.html" rel="external">
          "Ovulation induction with letrozole", section on 'Outcomes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          Clomiphene
         </a>
         citrate had been the first-line drug for this population for many years, with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         used as an alternative. However, both clomiphene and metformin appear to be less effective for live birth rates than
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         [
         <a href="#rid47">
          47
         </a>
         ]. In women with PCOS, an ovulatory rate of 80 percent and a cumulative pregnancy rate of 30 to 40 percent can be expected. Cumulative pregnancy rate is dependent on patient BMI, with higher BMI levels associated with lower cumulative pregnancy rate. (See
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multistep approach to the management of anovulatory infertility in women with PCOS is shown in the table  (
         <a class="graphic graphic_table graphicRef56718" href="/z/d/graphic/56718.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7425.html" rel="external">
          "Ovulation induction with letrozole"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         – Metformin is a drug whose major effect is to reduce hepatic glucose output and thereby lower serum insulin concentrations. Metformin has been used to promote ovulation either alone or in combination with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         , but clomiphene or
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         monotherapy appears to be superior to metformin monotherapy on live birth rates. Its role in treating infertility is limited [
         <a href="#rid1">
          1
         </a>
         ]. Clinical trial data supporting this are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'Anovulatory infertility'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Current guidelines recommend against the routine use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         in obese women with PCOS (including ovulation induction), except in women with glucose intolerance who have failed lifestyle interventions [
         <a href="#rid1">
          1,48
         </a>
         ]. Metformin therapy for PCOS and strategies for prevention of type 2 diabetes are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">
          "Prevention of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gonadotropin therapy
         </strong>
         – Another method to induce ovulation is administration of exogenous gonadotropins [
         <a href="#rid49">
          49
         </a>
         ]. A study of 225 women with PCOS treated over a 10-year period at one center found rates of ovulation and pregnancy of 72 percent and 45 percent, respectively, after the administration of low-dose gonadotropins [
         <a href="#rid50">
          50
         </a>
         ]. Exogenous gonadotropin therapy is reviewed in detail elsewhere. Women with PCOS and anovulatory infertility treated with gonadotropins are at high risk for ovarian hyperstimulation syndrome (OHSS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Exogenous gonadotropin regimens are complex and expensive and are best carried out by experienced clinicians; most clinicians recommend an assessment of fallopian tube patency before initiating these relatively aggressive therapies. (See
         <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">
          "Prevention of ovarian hyperstimulation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">
          "Overview of ovulation induction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thiazolidinedione therapy has been investigated for induction of ovulation [
         <a href="#rid8">
          8,51-53
         </a>
         ], but we do not suggest its use because of concern about its cardiovascular safety. (See
         <a class="local">
          'Insulin resistance/type 2 diabetes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although women with PCOS are not likely gonadotropin-releasing hormone (GnRH) deficient, pulsatile GnRH is moderately effective for ovulation induction. It is currently available in Europe, but not in the United States. In one study of 41 patients undergoing 114 ovulation induction cycles, 56 percent of women ovulated, and 40 percent of ovulatory patients achieved pregnancy [
         <a href="#rid54">
          54
         </a>
         ]. Ovulatory cycles were associated with lower BMI and fasting insulin, and higher baseline serum follicle-stimulating hormone (FSH) concentrations. Thus, pulsatile GnRH may be a reasonable option, particularly for lean women with PCOS.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3037375992">
         <span class="h2">
          Acupuncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infertility centers often offer acupuncture as an adjunctive therapy to women with PCOS undergoing ovulation induction or in vitro fertilization (IVF). However, available evidence suggests that it does not improve live birth rates when used alone or combined with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate (compared with sham acupuncture alone or with clomiphene) [
         <a href="#rid55">
          55,56
         </a>
         ]. The addition of acupuncture during IVF cycles does not improve outcomes. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H691428582">
         <span class="h2">
          Laparoscopic surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, wedge resection of the ovaries was a standard treatment for infertility in women with PCOS. However, this approach has been abandoned, both because of the efficacy of
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         and because of the high incidence of pelvic adhesions seen with wedge resection. A substitute for wedge resection, laparoscopic ovarian laser electrocautery, may be effective in some women with PCOS. However, given the other pharmacologic options for ovulation induction, surgery is not often indicated.
        </p>
        <p>
         For women who do not respond to ovulation induction with either
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         or
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate, laparoscopic ovarian drilling (also referred to as laparoscopic ovarian diathermy or electrocoagulation) is a surgical option for second-line treatment. When compared with gonadotropin therapy, another second-line treatment, ovarian drilling has similar efficacy but results in lower risk of high order multiple gestations or OHSS  (
         <a class="graphic graphic_table graphicRef82084" href="/z/d/graphic/82084.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid57">
          57,58
         </a>
         ]. Disadvantages of ovarian drilling include surgical risk and potential adhesion formation. Although laparoscopic ovarian drilling has been utilized for decades, the technique has never been standardized regarding the energy source, number of punctures, dose and duration per puncture, or whether one or both ovaries should be treated. Based on limited dose-ranging studies, three to six punctures per ovary at 40 W of coagulating (modulated) current for four seconds per puncture seems reasonable [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
         Ovarian drilling likely reduces ovarian secretion of androgens and proteins, resulting in an increase in LH and FSH secretion. In turn, following ovarian drilling, the ovary is more responsive to stimulation by endogenous gonadotropins favoring the growth of a dominant ovarian follicle and ovulation. Following ovarian drilling ovulatory cycles occur in approximately 80 percent of patients with a range of 30 to 90 percent, in published studies [
         <a href="#rid61">
          61
         </a>
         ]. The normalization of ovulatory function continued for many years in the majority of patients following ovarian drilling [
         <a href="#rid62">
          62-65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1586430">
         <span class="h2">
          In vitro fertilization
         </span>
         <span class="headingEndMark">
          —
         </span>
         If weight loss, ovulation induction with medications, and/or laparoscopic ovarian laser electrocautery are unsuccessful, the next step is IVF. Without co-interventions, women with PCOS are at increased risk for both multiple gestation and OHSS. Women with PCOS who undergo IVF have lower rates of OHSS with the transfer of frozen rather than fresh embryos. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions"
         </a>
         .)
        </p>
        <p>
         The risk of OHSS is high in women with PCOS undergoing controlled ovarian hyperstimulation for IVF, and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         administration before or during IVF cycles may reduce this risk [
         <a href="#rid66">
          66-68
         </a>
         ]. The best evidence comes from a meta-analysis of 12 randomized clinical trials including 1123 women with PCOS undergoing IVF or intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET) [
         <a href="#rid69">
          69
         </a>
         ]. The rate of OHSS in women randomized to metformin was 48 in 478 (10 percent), which was lower than in women not receiving metformin: 84 in 469, 18 percent (odds ratio [OR] 0.43; 95% CI, 0.24-0.78). The difference was only significant for women with a BMI &gt;26 kg/m
         <sup>
          2
         </sup>
         . In addition, like other previous reports [
         <a href="#rid67">
          67,68
         </a>
         ], metformin did not improve clinical pregnancy rates or live birth rates. Rates of OHSS are now as low as 1 percent in many programs who use multiple modifications of earlier regimens. (See
         <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"
         </a>
         .)
        </p>
        <p>
         For women at high risk for OHSS (overweight or obese with PCOS), adding
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         to the stimulation regimen remains a reasonable option to lower OHSS risk further. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'IVF pretreatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1913739918">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">
          "Society guideline links: Polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">
          "Society guideline links: Hirsutism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15605.html" rel="external">
          "Patient education: Polycystic ovary syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2163.html" rel="external">
          "Patient education: Polycystic ovary syndrome (PCOS) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – The management of polycystic ovary syndrome (PCOS) requires treatment of individual components of the syndrome, including menstrual dysfunction and the risk of endometrial hyperplasia, hyperandrogenism (hirsutism and acne), metabolic risk factors (obesity, glucose intolerance, and dyslipidemia), and, in some women, anovulatory infertility. The choice of therapy depends upon whether the patient is pursuing pregnancy or not. The treatment of hirsutism and approach to ovulation induction in women with PCOS are reviewed separately. (See
         <a class="local">
          'Overview of approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7425.html" rel="external">
          "Ovulation induction with letrozole", section on 'Ovulation induction in PCOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Women not pursuing pregnancy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Menstrual dysfunction
         </strong>
         – For women with PCOS, oligomenorrhea, and chronic anovulation we suggest combined estrogen-progestin oral contraceptive (COC) therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (see
         <a class="local">
          'Menstrual dysfunction'
         </a>
         above). The goal of COCs for these women is to prevent endometrial hyperplasia and provide contraception (as women with oligomenorrhea ovulate intermittently and unwanted pregnancy may occur). COCs are the mainstay of pharmacologic therapy for managing hyperandrogenic symptoms. For women with PCOS who choose not to or cannot take COCs, we typically use intermittent progestin therapy. (See
         <a class="local">
          'Menstrual dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Women with hyperandrogenic symptoms
         </strong>
         – For most women with hirsutism or other androgenic manifestations such as acne or female pattern hair loss, we also suggest starting with a COC (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (in addition to lifestyle measures). (See
         <a class="local">
          'Androgen excess'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We typically start with a COC containing 20 mcg of ethinyl estradiol combined with a progestin such as
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         or norethindrone acetate, progestins that have lower androgenicity, but similar VTE risk compared with levonorgestrel-containing COCs. Higher doses of ethinyl estradiol are needed in some women for optimal management of hyperandrogenic symptoms. Concerns about VTE risk with newer progestins and with
         <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">
          drospirenone
         </a>
         are reviewed separately. (See
         <a class="local">
          'Choice of oral contraceptive'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the patient is not satisfied with the clinical response to six months of COC monotherapy (for hyperandrogenic manifestations), we add
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         , an antiandrogen. (See
         <a class="local">
          'Androgen excess'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolic disorders
         </strong>
         – Weight loss (which can restore ovulatory cycles, improve metabolic risk, and possibly improve live birth rates) is the intervention for most women. Women who have already developed type 2 diabetes and/or dyslipidemia require specific interventions for these disorders. These disorders also require management during pregnancy. (See
         <a class="local">
          'Weight loss'
         </a>
         above and
         <a class="local">
          'Insulin resistance/type 2 diabetes'
         </a>
         above and
         <a class="local">
          'Dyslipidemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Women pursuing pregnancy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anovulatory infertility and ovulation induction
         </strong>
         – For women with PCOS and anovulatory infertility, attempts at weight loss should be tried first in those with obesity. If this does not restore ovulatory cycles, ovulation induction is required.
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          Letrozole
         </a>
         , an aromatase inhibitor, is now the first-line ovulation induction agent over
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate for women with PCOS. Before starting letrozole, the clinician must discuss that use of the drug is not approved for this indication, and that clomiphene is an alternative.  (
         <a class="graphic graphic_table graphicRef56718" href="/z/d/graphic/56718.html" rel="external">
          table 2
         </a>
         ) (See
         <a class="local">
          'Women pursuing pregnancy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7425.html" rel="external">
          "Ovulation induction with letrozole", section on 'Suggested approach'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98:4565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; :CD007506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin AW, Bergomi EJ, Dollahite JS, et al. Trust in Physicians and Medical Experience Beliefs Differ Between Women With and Without Polycystic Ovary Syndrome. J Endocr Soc 2018; 2:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids 2013; 78:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unlühizarci K, Keleştimur F, Bayram F, et al. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999; 51:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196:402.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; :CD003053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90:6364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2011; 17:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18:1928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update 2017; 23:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christ JP, Falcone T. Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). Obes Surg 2018; 28:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:3835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online 2017; 35:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol 2017; 10:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992; 74:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999; 50:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80:3327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cibula D, Sindelka G, Hill M, et al. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod 2002; 17:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011; :CD008565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tasali E, Chapotot F, Leproult R, et al. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocr Connect 2017; 6:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 2005; 11:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenwood EA, Pasch LA, Cedars MI, et al. Association among depression, symptom experience, and quality of life in polycystic ovary syndrome. Am J Obstet Gynecol 2018; 219:279.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhuang J, Wang X, Xu L, et al. Antidepressants for polycystic ovary syndrome. Cochrane Database Syst Rev 2013; :CD008575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98:4646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982; 38:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Dodson WC, Kunselman AR, et al. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. J Clin Endocrinol Metab 2016; 101:2658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly AC, Jewelewicz R. Alternate regimens for ovulation induction in polycystic ovarian disease. Fertil Steril 1990; 54:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz M, Karakoç A, Törüner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill S, Taylor AE, Martin KA, et al. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu XK, Stener-Victorin E, Kuang HY, et al. Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA 2017; 317:2502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim CE, Ng RW, Xu K, et al. Acupuncture for polycystic ovarian syndrome. Cochrane Database Syst Rev 2016; :CD007689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2012; :CD001122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moazami Goudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: A systematic review and meta-analysis. Iran J Reprod Med 2014; 12:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flyckt RL, Goldberg JM. Laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Semin Reprod Med 2011; 29:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amer SA, Li TC, Cooke ID. A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy. Hum Reprod 2003; 18:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seow KM, Juan CC, Hwang JL, Ho LT. Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects. Semin Reprod Med 2008; 26:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahuis MJ, Kose N, Bayram N, et al. Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins. Hum Reprod 2011; 26:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 2002; 17:2851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gjønnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998; 69:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naether OG, Baukloh V, Fischer R, Kowalczyk T. Long-term follow-up in 206 infertility patients with polycystic ovarian syndrome after laparoscopic electrocautery of the ovarian surface. Hum Reprod 1994; 9:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009; :CD006105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013; 120:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Y, Tu M, Huang Y, et al. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e2011995.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7421 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24151290" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30033227" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21328294" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lifestyle changes in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30140785" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trust in Physicians and Medical Experience Beliefs Differ Between Women With and Without Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23624028" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cancer risk and PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634377" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468995" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403436" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592687" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956435" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16189250" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20833639" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Exercise therapy in polycystic ovary syndrome: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2642485" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1559293" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10199797" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12923151" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199429" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12574218" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28486593" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29500679" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8784087" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215280" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219066" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15483106" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15292314" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15598674" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16501039" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28479118" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276778" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1530790" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Insulin resistance, secretion, and metabolism in users of oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468913" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593446" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756365" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261574" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21975784" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Statins for women with polycystic ovary syndrome not actively trying to conceive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21123449" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739562" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21569072" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191492" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29969586" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Association among depression, symptom experience, and quality of life in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23728677" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antidepressants for polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24092830" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6811336" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of body weight reduction on plasma androgens in obese, infertile women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8150098" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27172435" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25006718" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18243179" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Consensus on infertility treatment related to polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2116328" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Alternate regimens for ovulation induction in polycystic ovarian disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8923819" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12620440" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16335907" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15482765" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397835" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28655015" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27136291" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acupuncture for polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696324" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25408702" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21437828" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12871884" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18181088" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21576081" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407038" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9548160" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7714155" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long-term follow-up in 206 infertility patients with polycystic ovarian syndrome after laparoscopic electrocautery of the ovarian surface.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21982727" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370625" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23194199" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32744629" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
